Details of the Drug

General Information of Drug (ID: DM13P4C)

Drug Name

Salsalate

Synonyms

Diacesal; Diplosal; Disalcid; Disalicylsaeure; Disalyl; Nobacid; Salflex; Salical; Salina; Saloxium; Salsalato; Salsalatum;Salysal; Sasapirin; Sasapyrin; Sasapyrine; Sasapyrinum; Disalicylic acid; Sal Ester Sal; Salicylic Acid Salicylate; Salicyloylsalicylic acid; Salicylsalicylic acid; Disalcid (TN); O-Salicylcylsalicylsaeure; O-Salicyloylsalicylic Acid; O-Salicylsalicylic acid; Salflex (TN); Salicylic acid, bimolecular ester; Salicylic acid, salicylate; Salsalato [INN-Spanish]; Salsalatum [INN-Latin]; Salsitab (TN); Sasapyrine (JAN); Mono-Gesic (TN); Salsalate (USP/INN); Salsalate [USAN:INN:BAN]; Benzoic acid, 2-hydroxy-, 2-carboxyphenyl ester; 2-((2-Hydroxybenzoyl)oxy)benzoic acid; 2-(2-hydroxybenzoyl)oxybenzoic acid; 2-Carboxyphenyl salicylate; 2-Salicyloyloxybenzoic Acid; 2-{[(2-hydroxyphenyl)carbonyl]oxy}benzoic acid

Indication

Disease Entry	ICD 11	Status	REF
Rheumatoid arthritis	FA20	Approved	[1], [2]

Therapeutic Class

Antiinflammatory Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

258.23

Topological Polar Surface Area (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 1 hour (parent compound), and 3.5 - 16 hours (active metabolite) [3]

Chemical Identifiers

Formula: C14H10O5
IUPAC Name: 2-(2-hydroxybenzoyl)oxybenzoic acid
Canonical SMILES: C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O
InChI: InChI=1S/C14H10O5/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17/h1-8,15H,(H,16,17)
InChIKey: WVYADZUPLLSGPU-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 5161
ChEBI ID: CHEBI:9014
CAS Number: 552-94-3
DrugBank ID: DB01399
TTD ID: D0Y0JH

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase 1 (COX-1)	TT8NGED	PGH1_HUMAN	Inhibitor	[4], [5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Rheumatoid arthritis

ICD Disease Classification

FA20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Prostaglandin G/H synthase 1 (COX-1)	DTT	PTGS1	3.97E-03	0.16	0.43

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Salsalate (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Decreased renal excretion of Salsalate caused by Remdesivir mediated nephrotoxicity.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[15]
Tromethamine	DMOBLGK	Moderate	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Salsalate caused by Tromethamine mediated altered urine pH.	Acidosis [5C73]	[16]
Inotersen	DMJ93CT	Major	Increased risk of nephrotoxicity by the combination of Salsalate and Inotersen.	Amyloidosis [5D00]	[17]
ABT-492	DMJFD2I	Moderate	Additive CNS depression effects by the combination of Salsalate and ABT-492.	Bacterial infection [1A00-1C4Z]	[18]
Iodipamide	DMXIQYS	Major	Increased risk of nephrotoxicity by the combination of Salsalate and Iodipamide.	Cholelithiasis [DC11]	[19]
Ardeparin	DMYRX8B	Moderate	Increased risk of bleeding by the combination of Salsalate and Ardeparin.	Coronary thrombosis [BA43]	[20]
Danaparoid	DM6CLBN	Moderate	Increased risk of bleeding by the combination of Salsalate and Danaparoid.	Deep vein thrombosis [BD71]	[20]
Rivaroxaban	DMQMBZ1	Moderate	Increased risk of bleeding by the combination of Salsalate and Rivaroxaban.	Deep vein thrombosis [BD71]	[20]
SODIUM CITRATE	DMHPD2Y	Moderate	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Salsalate caused by SODIUM CITRATE mediated altered urine pH.	Discovery agent [N.A.]	[16]
Dexlansoprazole	DM1DBV5	Minor	Decreased absorption of Salsalate due to altered gastric pH caused by Dexlansoprazole.	Gastro-oesophageal reflux disease [DA22]	[21]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Salsalate and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[22]
Sodium acetate anhydrous	DMH21E0	Moderate	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Salsalate caused by Sodium acetate anhydrous mediated altered urine pH.	Hypo-osmolality/hyponatraemia [5C72]	[16]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of bleeding by the combination of Salsalate and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[23]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Salsalate and Exjade.	Mineral absorption/transport disorder [5C64]	[24]
Deflazacort	DMV0RNS	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Salsalate and Deflazacort.	Muscular dystrophy [8C70]	[25]
Prasugrel	DM7MT6E	Moderate	Increased risk of bleeding by the combination of Salsalate and Prasugrel.	Myocardial infarction [BA41-BA43]	[26]
Everolimus	DM8X2EH	Major	Increased risk of nephrotoxicity by the combination of Salsalate and Everolimus.	Renal cell carcinoma [2C90]	[27]
Temsirolimus	DMS104F	Major	Increased risk of nephrotoxicity by the combination of Salsalate and Temsirolimus.	Renal cell carcinoma [2C90]	[27]
Apixaban	DM89JLN	Moderate	Increased risk of bleeding by the combination of Salsalate and Apixaban.	Thrombosis [DB61-GB90]	[20]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Salsalate and Brilinta.	Thrombosis [DB61-GB90]	[17]
Insulin degludec	DMPL395	Moderate	Increased risk of hypoglycemia by the combination of Salsalate and Insulin degludec.	Type-1/2 diabete [5A10-5A11]	[28]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Salsalate and Plazomicin.	Urinary tract infection [GC08]	[29]
Betrixaban	DM2C4RF	Moderate	Increased risk of bleeding by the combination of Salsalate and Betrixaban.	Venous thromboembolism [BD72]	[20]
-----------


⏷ Show the Full List of 23 DDI Information of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	Drug information of Salsalate, 2008. eduDrugs.
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	New non-steroidal anti-rheumatic drugs: selective inhibitors of inducible cyclooxygenase. Med Klin (Munich). 1998 Jul 15;93(7):407-15.
5	Aspirin and NSAID sensitivity. Immunol Allergy Clin North Am. 2004 Aug;24(3):491-505, vii.
6	The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
7	Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
8	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9	Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
10	Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
11	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
12	Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
13	Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
14	Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.
15	Cerner Multum, Inc. "Australian Product Information.".
16	Balali-Mood M, Prescott LF "Failure of alkaline diuresis to enhance diflunisal elimination." Br J Clin Pharmacol 10 (1980): 163-5. [PMID: 7426277]
17	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
19	Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
20	Richards JR, Garber D, Laurin EG, et al. Treatment of cocaine cardiovascular toxicity: a systematic review.?Clin Toxicol (Phila). 2016;54(5):345-364. [PMID: 26919414]
21	Miner PB Jr, Fort JG, Zhang Y. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325?mg + immediate-release omeprazole 40?mg) or enteric-coated aspirin 325?mg + enteric-coated omeprazole 40?mg - a randomised, phase 1, crossover study.?Aliment Pharmacol Ther. 2013;38(1):62-71. [PMID: 23692061]
22	EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
23	Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
24	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
25	Baer PA, Shore A, Ikeman RL "Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis." Arthritis Rheum 30 (1987): 345-7. [PMID: 3566826]
26	Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN.
27	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
28	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
29	Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]